IntriCon Reports Fourth Quarter and Full Year 2018 Results
Medical and Value Hearing Health Performance Drive Record
Quarterly Revenue; Company Provides Guidance for 2019
ARDEN HILLS, Minn.–(BUSINESS WIRE)–IntriCon Corporation (NASDAQ: IIN), a designer, developer,
manufacturer and distributor of miniature and micro-miniature body-worn
devices, today announced financial results for its fourth quarter and
year ended December 31, 2018.
Recent Highlights:
-
Record quarterly revenue of $30.8 million, a 41.1 percent increase
over the prior-year fourth quarter; -
Gross margin of 30.0 percent, consistent with the comparable
prior-year period; - Net income per share of $0.09 versus $0.05 in the 2017 fourth quarter;
-
Grew revenue from its largest medical customer by 74.8 percent
compared to fourth quarter 2017; -
Increased indirect-to-end-consumer hearing healthcare revenue by 79.9
percent year over year; - Continued buildout of infrastructure to meet future demand;
-
Acquired source code from Soundperience for its Sentibo Smart Brain
self-fitting software; and -
Hired Doug Pletcher as vice president of medical biotelemetry business
development.
“Our medical and indirect-to-end-consumer value hearing health
businesses continued to drive strong top-line performance, leading to
another quarter of record revenue,” said Mark S. Gorder, president and
chief executive officer of IntriCon. “I’m pleased with the meaningful
progress we made in 2018 towards advancing our key growth initiatives,
bolstering our medical leadership team, and expanding our technology.
“I am confident that we are entering 2019 in our strongest position to
date. We have the capital to pursue strategic initiatives and a
well-developed infrastructure to support our efforts in medical and
value hearing health. I believe that we are well positioned in the early
stages of long-term, sustained growth within our core markets. The
diabetes market is experiencing tremendous growth, with continuous
glucose monitoring (CGM) a critical component to serving the needs of
many diabetics. And as the value-hearing healthcare space emerges, we
believe we are at the forefront of providing affordable and accessible
solutions to unserved or underserved hearing-impaired Americans.”
Fourth Quarter 2018 Financial Results
For the 2018 fourth
quarter, the company reported net revenue of $30.8 million, up 41.1
percent from $21.8 million in the comparable prior-year period. The
increase was primarily due to year-over-year revenue gains from the
company’s largest medical customer and growth in its value-based
indirect-to-end-consumer hearing healthcare business.
Fourth-quarter gross margins were 30.0 percent, consistent with 30.0
percent in the prior-year fourth quarter. Gross margins in the quarter
were constrained by costs related to additional infrastructure
investments.
Operating expenses for the fourth quarter were $8.2 million, compared to
$6.1 million in the comparable prior-year period. The increase stemmed
from increased advertising investments at Hearing Help Express (HHE),
and support costs related to key initiatives to drive overall business
growth.
The company posted net income of $868,000, or $0.09 per diluted share,
versus $396,000 or $0.05 per diluted share, for the 2017 fourth quarter.
Full Year 2018 Financial Results
For the full year ended
December 31, 2018, the company reported revenue of $116.5 million, up
28.5 percent from $90.6 million in 2017.
Gross margins were 31.9 percent, up from 29.5 percent in 2017. The
increase in margin was primarily due to the increased volume throughout
2018.
Operating expenses were $30.0 million, compared to $24.2 million in the
prior year. The increase stemmed from increased advertising investments
at HHE, and support costs related to key initiatives to drive overall
business growth.
Net income attributable to shareholders was $5.5 million, or $0.64 per
diluted share, versus $2.1 million, or $0.28 per diluted share, in 2017.
Guidance for Full Year 2019
The company anticipates 2019
revenue to range between $128 million to $133 million. Gross margins for
the 2019 full year are expected to be approximately 30.0 to 31.5
percent. In general, the company anticipates linear revenue growth and
gross margin improvement through 2019, however this could be impacted by
commercial product launch timing from its largest customer and mix
shifts between product lines.
Business Update
Revenue in the company’s medical business
increased 64.8 percent in the 2018 fourth quarter over the comparable
prior-year period. The gain was primarily driven by the ongoing
production of wireless CGM systems for the company’s largest customer.
Revenue to this customer increased 74.8 percent in the fourth quarter
over the comparable prior year period. The company remains very well
positioned with this customer for 2019, providing key system components
including CGM systems, sensor assembly and related accessories.
During the year, the company expanded its infrastructure to support
anticipated growth from its current medical customers and other new
business development efforts. Expansion efforts include a newly leased
37,000-square-foot medical manufacturing and clean room facility in
Minnesota, an additional 10,000-square-foot medical assembly space in
Singapore, 13 new molding presses and a high-speed printed circuit board
assembly line. In addition to these investments, our current customers
invested several million dollars in tooling and automation within our
facilities. While the company has begun limited production on certain
products, it is still working with current medical customers to complete
required validation and qualification of several key production lines.
Recently, the company hired Doug Pletcher as Vice President of Medical
Business Development. Pletcher has more than 25 years of executive
management and business development experience in the medical device
industry. In this new role, Pletcher is responsible for sales and
marketing of new product platforms into the medical biotelemetry market.
On the hearing health front, total revenue increased by 10.3 percent
over the prior-year fourth quarter, led by the company’s value-based
indirect-to-end-consumer business, which posted strong revenue growth of
79.9 percent. This gain was partially offset by a temporary decline in
the direct-to-end-consumer channel and expected continued waning in the
conventional sales channel.
The company continues to build its value hearing health technology
portfolio, with wireless and self-fitting technologies. Last month, the
company closed on its acquisition of the Sentibo Smart Brain
self-fitting software source code from Soundperience, positioning the
company to capitalize on the pending over-the-counter (OTC) hearing aid
regulation. Sentibo Smart Brain self-fitting software is designed to
improve both channel productivity and the quality of first-time
fittings, resulting in lower prices, greater access and increased
customer satisfaction.
Conference Call
The company will hold a conference call
today, Tuesday, February 19, 2019, beginning at 4 p.m. CT. To join the
conference call, dial: 1-855-719-5012 and provide the conference ID
number 7881455 to the operator. To access the replay, dial
1-888-203-1112 and enter passcode 7881455.
About IntriCon Corporation
Headquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures miniature
and micro-miniature body-worn devices. These advanced products help
medical, healthcare and professional communications companies meet the
rising demand for smaller, more intelligent and better-connected
devices. IntriCon has facilities in the United States, Asia, the United
Kingdom and Europe. The company’s common stock trades under the symbol
“IIN” on the NASDAQ Global Market. For more information about IntriCon,
visit www.intricon.com.
Forward-Looking Statements
Statements made in this release
and in IntriCon’s other public filings and releases that are not
historical facts or that include forward-looking terminology, including
estimates of future results, are “forward-looking statements” within the
meaning of the Securities Exchange Act of 1934, as amended. These
forward-looking statements may be affected by known and unknown risks,
uncertainties and other factors that are beyond IntriCon’s control, and
may cause IntriCon’s actual results, performance or achievements to
differ materially from the results, performance and achievements
expressed or implied in the forward-looking statements. These risks,
uncertainties and other factors are detailed from time to time in the
company’s filings with the Securities and Exchange Commission, including
the Annual Report on Form 10-K for the year ended December 31, 2017. The
company disclaims any intent or obligation to publicly update or revise
any forward-looking statements, regardless of whether new information
becomes available, future developments occur or otherwise.
| INTRICON CORPORATION | ||||||||||||||||||
| MARKET REVENUE | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| FOURTH QUARTER | YEAR TO DATE | |||||||||||||||||
| ($ in 000’s) | 2018 | 2017 | Growth | 2018 | 2017 | Growth | ||||||||||||
| Medical | $ | 20,158 | $ | 12,232 | 64.8 | % | $ | 75,645 | $ | 53,452 | 41.5 | % | ||||||
| Diabetes | 17,666 | 10,104 | 74.8 | % | 65,197 | 43,365 | 50.3 | % | ||||||||||
| Other Medical | 2,492 | 2,128 | 17.1 | % | 10,448 | 10,087 | 3.6 | % | ||||||||||
| Hearing Health | 8,761 | 7,943 | 10.3 | % | 33,578 | 31,019 | 8.2 | % | ||||||||||
| Value Based Direct-to-End-Consumer | 1,525 | 1,904 | -19.9 | % | 6,858 | 6,492 | 5.6 | % | ||||||||||
| Value Based Indirect-to-End-Consumer | 3,681 | 2,046 | 79.9 | % | 11,949 | 7,908 | 51.1 | % | ||||||||||
| Legacy OEM | 3,555 | 3,993 | -11.0 | % | 14,771 | 16,619 | -11.1 | % | ||||||||||
| Professional Audio Communications | 1,886 | 1,662 | 13.5 | % | 7,239 | 6,166 | 17.4 | % | ||||||||||
| Total | $ | 30,805 | $ | 21,837 | 41.1 | % | $ | 116,462 | $ | 90,637 | 28.5 | % | ||||||
| INTRICON CORPORATION | ||||||||||||||||
| Consolidated Condensed Statements of Operations | ||||||||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | December 31, | December 31, | |||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
|
(as adjusted) |
(as adjusted) |
|||||||||||||||
| Revenue, net | $ | 30,805 | $ | 21,837 | $ | 116,462 | $ | 90,637 | ||||||||
| Cost of sales | 21,568 | 15,290 | 79,299 | 63,890 | ||||||||||||
| Gross profit | 9,237 | 6,547 | 37,163 | 26,747 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 3,640 | 2,590 | 12,369 | 9,447 | ||||||||||||
| General and administrative | 3,575 | 2,378 | 13,009 | 10,339 | ||||||||||||
| Research and development | 978 | 1,146 | 4,671 | 4,458 | ||||||||||||
| Total operating expenses | 8,193 | 6,114 | 30,049 | 24,244 | ||||||||||||
| Operating income | 1,044 | 433 | 7,114 | 2,503 | ||||||||||||
| Interest (income) expense, net | 139 | (168 | ) | (314 | ) | (716 | ) | |||||||||
| Other expense | (189 | ) | (39 | ) | (769 | ) | (367 | ) | ||||||||
|
Income from continuing operations before income taxes and discontinued operations |
994 | 226 | 6,031 | 1,420 | ||||||||||||
| Income tax expense (benefit) | 126 | (157 | ) | 484 | 8 | |||||||||||
| Income before discontinued operations | 868 | 383 | 5,547 | 1,412 | ||||||||||||
| Loss on sale of discontinued operations, net of income taxes | – | – | – | (164 | ) | |||||||||||
| Loss from discontinued operations, net of income taxes | – | – | – | (128 | ) | |||||||||||
| Net Income | 868 | 383 | 5,547 | 1,120 | ||||||||||||
| Less: Loss allocated to non-controlling interest | – | (13 | ) | – | (938 | ) | ||||||||||
| Net Income attributable to shareholders | $ | 868 | $ | 396 | $ | 5,547 | $ | 2,058 | ||||||||
| Basic income (loss) per share attributable to shareholders: | ||||||||||||||||
| Continuing operations | $ | 0.10 | $ | 0.06 | $ | 0.73 | $ | 0.34 | ||||||||
| Discontinued operations | – | – | – | (0.04 | ) | |||||||||||
| Net income per share: | $ | 0.10 | $ | 0.06 | $ | 0.73 | $ | 0.30 | ||||||||
| Diluted income (loss) per share attributable to shareholders: | ||||||||||||||||
| Continuing operations | $ | 0.09 | $ | 0.05 | $ | 0.64 | $ | 0.32 | ||||||||
| Discontinued operations | – | – | – | (0.04 | ) | |||||||||||
| Net income per share: | $ | 0.09 | $ | 0.05 | $ | 0.64 | $ | 0.28 | ||||||||
| Average shares outstanding: | ||||||||||||||||
| Basic | 8,647 | 6,883 | 7,599 | 6,852 | ||||||||||||
| Diluted | 9,439 | 7,646 | 8,630 | 7,307 | ||||||||||||
| INTRICON CORPORATION | ||||||||
| Consolidated Condensed Balance Sheets | ||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||
| (Unaudited) | ||||||||
| December 31, | December 31, | |||||||
| 2018 | 2017 | |||||||
|
(as adjusted) |
||||||||
| Current assets: | ||||||||
| Cash, cash equivalents and restricted cash | $ | 8,047 | $ | 1,017 | ||||
| Available for sale securities | 38,093 | – | ||||||
|
Accounts receivable, less allowance for doubtful accounts of $807 at December 31, 2018 and $332 at December 31, 2017 |
11,479 | 9,052 | ||||||
| Inventories | 18,981 | 13,708 | ||||||
| Contract assets | 5,624 | 2,979 | ||||||
| Other current assets | 2,320 | 1,544 | ||||||
| Total current assets | 84,544 | 28,300 | ||||||
| Machinery and equipment | 37,161 | 40,124 | ||||||
| Less: Accumulated depreciation | 25,429 | 32,949 | ||||||
| Net machinery and equipment | 11,732 | 7,175 | ||||||
| Goodwill | 10,808 | 10,808 | ||||||
| Intangible assets | 2,585 | 2,740 | ||||||
| Investment in partnerships | 2,091 | 1,616 | ||||||
| Other assets, net | 3,488 | 3,835 | ||||||
| Total assets | $ | 115,248 | $ | 54,474 | ||||
| Current liabilities: | ||||||||
| Current maturities of long-term debt | $ | – | $ | 2,040 | ||||
| Accounts payable | 13,191 | 10,423 | ||||||
| Accrued salaries, wages and commissions | 4,409 | 3,113 | ||||||
| Other accrued liabilities | 4,014 | 3,739 | ||||||
| Total current liabilities | 21,614 | 19,315 | ||||||
| Long-term debt, less current maturities | – | 9,321 | ||||||
| Other postretirement benefit obligations | 377 | 455 | ||||||
| Accrued pension liabilities | 739 | 772 | ||||||
| Other long-term liabilities | 544 | 3,172 | ||||||
| Total liabilities | 23,274 | 33,035 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
|
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,664 and 6,900 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively |
8,664 | 6,900 | ||||||
| Additional paid-in capital | 84,999 | 21,581 | ||||||
| Accumulated deficit | (509 | ) | (6,056 | ) | ||||
| Accumulated other comprehensive loss | (927 | ) | (733 | ) | ||||
| Total shareholders’ equity | 92,227 | 21,692 | ||||||
| Non-controlling interest | (253 | ) | (253 | ) | ||||
| Total equity | 91,974 | 21,439 | ||||||
| Total liabilities and equity | $ | 115,248 | $ | 54,474 | ||||
Contacts
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investorrelations@intricon.com